Search
Get to know Marissa Gredler, a postdoctoral fellow in the Sloan Kettering Institute.
An MSK study found a rise in lumpectomies and a decline in mastectomies — reversing a trend that experts say was leading to the overtreatment of breast cancer.
A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.
An innovative technique called stereotactic hypofractionated accelerated radiation to the prostate – aka SHARP - safely and effectively delivers powerful doses of radiation directly to the patient’s tumor with incredible precision.
New MSK research showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop graft-versus-host disease (GVHD); and sheds new light on cell state changes in prostate cancer.
Recent data from Memorial Sloan Kettering shows that a real-time breast ultrasound exam after second opinion review of outside, static breast ultrasound images led to a change in the initially prescribed management in 32.5 percent of included patients.
Traveling with cancer can be done, even if you’re in active treatment. Plan ahead so that you can fully enjoy your vacation.
A major research initiative could pave the way for new stem cell therapies for people with damaged immune systems.
A vital part of MSK's mission is to get patients back to feeling like themselves.
MSK’s comprehensive program for patients with upper tract urothelial carcinoma (UTUC) offers kidney-sparing treatment options whenever possible.